News
TytoCare closes $25M+ growth round and names new CEO to scale AI-first remote examination platform
Insight Partners led the growth round with HOOP, OliveTree, OrbiMed, Qumra Capital, and Qualcomm Ventures participating. TytoCare simultaneously appointed Adam Pellegrini, former CVS Health EVP, as CEO. The company is repositioning from a general telehealth device company toward chronic disease management — specifically congestive heart failure, COPD, post-surgical recovery, and oncology monitoring — pairing its FDA-cleared physical examination hardware with SaMD AI algorithms for lung auscultation, cardiac screening, and dermatological assessment.
- funding
- telehealth
- remote-care
- chronic-disease
- FDA
TytoCare’s strategic repositioning is the signal worth watching here, more than the round size. The company has been selling its handheld examination kit — a device that attaches different modules to examine ears, throat, heart, lungs, and skin — for several years. Early traction came from telehealth-first health plans and employers trying to reduce urgent care visits. What the new CEO and funding round signal is a deliberate pivot toward chronic disease populations: CHF, COPD, post-surgical, oncology.
That is a meaningfully different market. Chronic disease monitoring is sold to different buyers (health plans managing high-cost members, ACOs with downside risk), has different reimbursement pathways (remote patient monitoring CPT codes, which CMS has expanded three times since 2020), and competes with a different set of incumbents (Biofourmis, Current Health, Rimidi) than the general telehealth kit market.
The AI SaMD layer is the part that matters most for differentiation. TytoCare’s auscultation analysis — the lung sound analysis that supports evaluation of cardiopulmonary status — turns the physical examination data into a structured clinical output rather than a raw audio recording a distant clinician has to interpret. That is the difference between a “ship the exam data” product and a “ship the clinical finding” product. Getting the FDA clearance pathway right for each additional AI indication is what separates TytoCare from commodity remote examination hardware.
Adam Pellegrini’s background at CVS Health (which runs MinuteClinic and a large pharmacy benefits business) is interesting context for distribution: if TytoCare can get its platform into CVS’s chronic disease management programs or pharmacy-based care programs, the distribution problem shrinks considerably.
Related coverage: health-system copilots topic.
Primary source: Read the full original on TytoCare ↗